Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

2008

CASH AND CASH EQUIVALENTS $4,502 $3,313

ACCOUNTS RECEIVABLE 7,111 6,761

TOTAL INVENTORIES 8,847 8,416

OTHER 4,609 6,025

TOTAL CURRENT ASSETS 25,069 24,515

NET PROPERTY, PLANT AND EQUIPMENT 19,724 20,640

NET GOODWILL AND OTHER INTANGIBLE ASSETS 91,238 94,000

OTHER NON-CURRENT ASSETS 4,648 4,837

TOTAL ASSETS $140,679 $ 143,992

ACCOUNTS PAYABLE $6,006 $6,775

ACCRUED AND OTHER LIABILITIES 9,653 10,154

TAXES PAYABLE 1,442 945

DEBT DUE WITHIN ONE YEAR 21,140 13,084

TOTAL CURRENT LIABILITIES 38,241 30,958

LONG-TERM DEBT 18,307 23,581

OTHER 19,569 19,959

TOTAL LIABILITIES 76,117 74,498

TOTAL SHAREHOLDERS' EQUITY 64,562 69,494

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $140,679 $ 143,992

Certain amounts for prior periods were reclassified to conform with the

fiscal 2009 presentation

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

(Amounts in Millions Except Per Share Amounts)

Consolidated Earnings Information

JAS QUARTER

JAS 08 JAS 07 % CHG

NET SALES $22
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/9/2009)... New England Peptide, a Massac...ides and polyclonal antibodies for drug and vaccin...customers with alternative chemical solutions in t...eading New England Peptide,s strategic usage of ne...obert Hammer and Dr. Robert Hodges. , ...
(Date:1/8/2009)...OSTON, Jan. 8 The Allia...ngly opposes the new marketing campaigns by Wal-Ma... to provide free prescribed antibiotics to custome...they will actually lead to increased costs in the ...esistance. While the public,s need for affordable...
(Date:1/8/2009)...ALLAS, Jan. 8 A study released thi...are suffering from multiple chronic diseases shine... U.S. health care system to one that focuses on pr...Preventive Medicine, the leader in disease prevent...bin/prnh/20080506/NETU129LOGO ) , , The study...
(Date:1/8/2009)...alifornia Assembly Member Tom Torlakson Introduces...re-USNewswire/ -- Today, Lung Cancer Alliance-Ca...er Tom Torlakson (D-11th District) for his continu... funding for lung cancer research. For the third ... cancer research is being considered in the Califo...
Breaking Medicine News(10 mins):Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 3Health News:Antibiotics as Loss Leaders? 2Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2
...ty of Southern California in Los Angeles, study th...obese or overweight people and found// that the no...han their obese counterparts. The study that was ...an Dietetic Association stated that the compositio...
...s has gone against the general notion and has show...overstrain the emergency rooms// in hospitals in t...stated that most of the Hispanics were uninsured a...heir conditions worsen to the point where they wou...
...luding Tata Steel have joined hands with the Jhark... Trust to ensure medicare to the state's Below Pov...ed to contribute Rs 25 crore for the said purpose ...sar Group were expected to confirm their respectiv...
...stration (FDA) and Roxane Labs have issued a natio...re used in patients with severe// rheumatoid arthr...revent rejection. "It was discovered that a single...lot 558470A contained Methotrexate tablets USP 2.5...
Other Medicine News:Health News:Better Weight Management Can be Achieved By Increased Intake Of Fibre & Fruits 2
(Date:1/7/2009)... INDIANAPOLIS, Jan. 7 El...y that it received a complete response letter from...olanzapine long-acting,injection (LAI) for acute ...lts. Lilly is continuing to work with the agency o...A does not require any additional clinical trials ...
(Date:1/7/2009)...JING, Jan. 7 Tiantan Puhua Hospita...m ), the worldwide leader in using stem cells to e... today six new globally experienced additions to i...xpand the hospital,s treatment capabilities for gr...The six senior doctors include the distinguished D...
(Date:1/6/2009)... YORK, Jan. 6 The Micha... million to four industry research teams for pre-c...arkinson,s disease. , , The funding was awarded...Initiative. This program, first launched in 2006,... Parkinson,s research. TDI is part of MJFF,s foc...
(Date:1/5/2009)... DIEGO, Jan. 5 Cylene Pharmaceutic...I clinical trial of its oral CK2 protein kinase in...tumors, Castleman,s disease, or multiple myeloma. ...trial are determination of safety, tolerance and P...ate dose for Phase II trials. In addition, multipl...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 1Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 2Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 3TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 1TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5
... Data presented at 12th Congress of European Hemat...e-FirstCall/ -- Alexion,Pharmaceuticals, Inc. toda...II studies examining Soliris(TM) (eculizumab) for ...ia (PNH) at the 12th,Congress of European Hematolo...on (EHA) in Vienna. These presentations,included: ...
...ARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory N...liminary data from the,ongoing phase III study for...relin do not support the expected sustainable bloo... in all patients.,Therefore, Ipsen has decided not...n the protocol. No safety concerns have,been obser...
Other Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium.
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches.
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches.
Left angled 5 mm blunt hook. Overall length: 9.9 inches.
Medicine Products: